Roth Capital Cuts Price Target on Curis (CRIS) Following 2Q Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
FBR Capital Starts Curis (CRIS) at Outperform
August 10, 2015 5:44 PM EDTFBR Capital initiates coverage on Curis (NASDAQ: CRIS) with a Outperform rating and a price target of $6.00.
Analyst Christopher S. James, M.D. commented, " Curis is a biotech company developing oral small molecule drugs targeting critical pathways in cancer that are either discovered internally or acquired through... More
Curis (CRIS) Reports In-Line Q2 EPS
August 6, 2015 7:07 AM EDTCuris (NASDAQ: CRIS) reported Q2 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $3.5 million.
For earnings history and earnings-related data on Curis (CRIS) click here.
... More